This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


ANI Pharmaceuticals, Inc.

Drug Names(s): transdermal testosterone gel

Description: Bio-T-Gel is a once-daily transdermal testosterone gel.

Deal Structure: BioSante and Teva
In December 2002, BioSante signed a development and license agreement with Teva Pharmaceuticals, a wholly owned subsidiary of Teva Pharmaceutical Industries, under which Teva USA and BioSante will collaborate on the development of a hormone therapy product for the U.S. market. Upon signing the U.S. development and license agreement, BioSante received an upfront payment of $1.5 million. In addition, Teva will pay BioSante development and sales-related milestone payments plus royalties on sales of the product commercialized in this collaboration. In exchange, BioSante granted Teva exclusive rights to develop and market a certain hormone therapy product. Teva also is responsible for continued development, regulatory filings and all manufacturing and marketing associated with the product.

In June 2007, BioSante announced that it and a subsidiary of Teva Pharmaceutical Industries have signed an amendment to their development and license agreement under...See full deal structure in Biomedtracker

Partners: Teva Pharmaceutical Industries Ltd.

Bio-T-Gel News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug